The biotech sector may be a big winner into the year’s end
The 
XBI has been one of the worst performing ETFs this year as the biotech sector faced important headwinds coming from Washington. A cap on prices has been since dropped, which is extremely beneficial for the long term. In addition, from a historical perspective, November and December are this ETF’s strongest months. The candidates for the Ash conference of biotechs will be announced this week which may prove to be yet another positive catalyst. We are long some XBI calls for January and continue to hold our small bio spec play, $MBIO.
XBI has been one of the worst performing ETFs this year as the biotech sector faced important headwinds coming from Washington. A cap on prices has been since dropped, which is extremely beneficial for the long term. In addition, from a historical perspective, November and December are this ETF’s strongest months. The candidates for the Ash conference of biotechs will be announced this week which may prove to be yet another positive catalyst. We are long some XBI calls for January and continue to hold our small bio spec play, $MBIO. 
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.